Co-Authors
This is a "connection" page, showing publications co-authored by John Hart and Mitchell C. Posner.
Connection Strength
0.428
-
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
Score: 0.180
-
Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery. 2003 Oct; 134(4):656-65; discussion 665-6.
Score: 0.058
-
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
Score: 0.048
-
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 01; 8(1):37-48.
Score: 0.038
-
Complete endoscopic mucosal resection is effective and durable treatment for Barrett's-associated neoplasia. Clin Gastroenterol Hepatol. 2014 Dec; 12(12):2002-10.e1-2.
Score: 0.030
-
Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience. Am J Gastroenterol. 2009 Nov; 104(11):2684-92.
Score: 0.022
-
Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? Clin Gastroenterol Hepatol. 2008 Feb; 6(2):159-64.
Score: 0.019
-
Presence of distal intramural spread after preoperative combined-modality therapy for adenocarcinoma of the rectum: what is now the appropriate distal resection margin? Surgery. 2005 Oct; 138(4):658-63; discussion 663-4.
Score: 0.017
-
Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res. 2005 Apr 15; 65(8):3146-54.
Score: 0.016